Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2014-01-01
|
| Series: | Drug Target Insights |
| Online Access: | https://doi.org/10.4137/DTI.S16524 |